Microsoft Word - RadBio_Programme_ParisSept2017_verAug31
|
00_RadBio_Programme_Paris_September 2017.pdf |
1 |
|
0_MJ_Intro_Paris17_WS |
4-5 |
|
1_VG_Introduction Paris 2017 |
46 |
|
2_2017_Koritzinsky_Hallmarks of Cancer |
66-67 |
|
3_2017_Koritzinsky_Cell Death |
136-137 |
|
4 _cell_surv_Coppes 2017 Paris |
214-215 |
|
5_MJ_Models_Paris17_WS |
292-293 |
|
6_WD_Pathogenesis of NT effects |
346-347 |
|
7_KH_Clinical side effects |
428-429 |
|
8_MJ_LQapproach_Paris17_WS |
558-559 |
|
9_2017_Koritzinsky_MolBasisDNAdamageResponse |
612-613 |
|
10 _WD_NT radiosensitivity and fractionation |
674-675 |
|
11_WD_NT overall treatment time |
718-719 |
|
12_VG_HFAF Paris 2017 |
786 |
|
13_MJ_LQpractice_Paris17_WS |
808-809 |
|
14_MJ_KH_LQ models examples of calculations |
844-845 |
|
15 _WD_Volume effects in RT |
912-913 |
|
16_MK_HypoxiaTumorMicroenvironment |
990-991 |
|
17_KH_Hypoxia modification |
1076-1077 |
|
18_MJ_DoseRespRels_Paris17_WS |
1198-1199 |
|
19_MJ_LETandRBE_Paris17_WS |
1258-1259 |
|
19_VG_KH_Excercise Lower GU |
1314-1315 |
|
20_MK_Biological_modifiers_preclinical |
1408-1409 |
|
21_KH_Biological response modifiers |
1490-1491 |
|
22_RC_Biological modifiers of normal tissue effects Paris 2017 |
1590-1591 |
|
23_VG RT_CH Paris 2017 |
1670 |
|
24_RC_Retreatement tolerance Paris 2017 |
1688-1689 |
|
25_VG Funct Imag Paris 2017 |
1770 |
|
26_KH_Tumor growth and response to irradiation |
1792-1793 |
|
27_RC_Dose-rate & brachyther paris 2017 |
1898-1899 |
|
28_VG_Particles in RT |
1958 |
|
29_MJ_RadnInducedMalig_Paris17_WS |
1988-1989 |